Crystal's Coder Hub💉 CPT 96366 — Intravenous Infusion, for Therapy, Prophylaxis, or Diagnosis; Each Additional Hour (Add-On)
Quick Reference
wRVU: 0.18 | Global Period: ZZZ | Assistant Payable: No | Bilateral Indicator: 3 The ZZZ global period designates 96366 as an add-on code — it inherits the global period of whatever primary procedure code it is reported alongside, and it can never be billed alone. A bilateral indicator of 3 means the bilateral surgery concept does not apply; IV infusions are systemic procedures and laterality modifiers (-RT, -LT, -50) are not relevant. This code carries a work RVU of only 0.18, reflecting that the dominant resource cost is the practice expense (drug, IV supplies, nursing time) rather than physician cognitive effort. The 2026 national average Medicare non-facility and facility payments are approximately 33.4009.1
📋 Clinical Description
CPT 96366 is a time-based add-on code that reports each additional hour of a therapeutic, prophylactic, or diagnostic intravenous infusion beyond the first hour, which is reported with the primary infusion code 96365. The AMA defines a “full additional hour” for reporting purposes as any infusion interval of 31 minutes or more beyond a completed 60-minute increment; intervals of 30 minutes or fewer beyond the last full hour are not separately reportable.2 This means that if a total infusion runs 91-150 minutes, one unit of 96366 may be billed; 151-210 minutes supports two units; and so on, counting in 60-minute increments with a 31-minute minimum per additional unit.
CPT 96366 is strictly a non-chemotherapy, non-hydration add-on code. It is used only when the primary infusion is a therapeutic, prophylactic, or diagnostic substance — such as monoclonal antibodies (e.g., infliximab, rituximab, natalizumab), IV immunoglobulin (IVIG), antivirals, antibiotics, or other non-chemo drugs. For chemotherapy infusions, 96415 is the analogous add-on; for hydration infusions, 96361 applies. The code family follows a strict CPT hierarchy that determines which code serves as the primary (highest-level) service when multiple drugs are infused in the same encounter.2
This procedure may be performed in the following clinical contexts:
- Biologic infusion therapy for autoimmune disease — Drugs such as infliximab (Remicade), tocilizumab (Actemra), or vedolizumab (Entyvio) for rheumatoid arthritis, Crohn’s disease, or ulcerative colitis frequently require infusion times of 2-3 hours per protocol. 96365 captures the first hour; 96366 is reported ×1 or ×2 depending on total infusion duration. Protocol-mandated infusion rates that extend beyond 60 minutes directly support medical necessity for additional-hour units.
- IV immunoglobulin (IVIG) administration — IVIG infusions for conditions such as primary immune deficiencies, CIDP, G61.81, Guillain-Barré syndrome G61.0, and immune thrombocytopenic purpura (ITP) routinely run 4-8+ hours depending on the product, dose, and patient tolerance. Multiple units of 96366 are expected and supported when total infusion time is documented with start/stop times.
- Antiviral and antifungal therapy in infectious disease — IV antivirals (e.g., acyclovir for severe herpes infections, ganciclovir for CMV) and antifungals (e.g., amphotericin B, micafungin) have specific infusion rate requirements driven by drug pharmacokinetics and toxicity profiles, commonly running 1-4 hours per dose. 96365 plus 96366 ×1-3 is appropriate when time documentation supports the total duration.
- Oncologic supportive care infusions — Non-chemotherapy supportive drugs such as IV bisphosphonates (zoledronic acid), IV iron preparations (ferric carboxymaltose, low molecular weight iron dextran), and anti-emetics administered by prolonged infusion may qualify for 96366 when infusion time exceeds one hour. Verify drug-specific CPT guidance, as some preparations have dedicated HCPCS codes.
- Neurology infusion therapy — Natalizumab (Tysabri) for relapsing MS G35.A and eculizumab (Soliris) for rare neuromuscular disorders require IV infusion with a standard 60-minute infusion time plus a mandatory 1-hour observation period; the observation does not itself extend the infusion time for coding, but drugs like rituximab for neuromyelitis optica may have multi-hour infusion protocols that do generate 96366 units.
🔬 Anatomical & Procedural Considerations
| Variant | Mechanism | Key Notes |
|---|---|---|
| Peripheral IV Infusion | A short-bore intravenous catheter is placed in a peripheral vein (commonly antecubital, forearm, or hand). The drug solution is infused via gravity drip or electronic infusion pump, and the rate is controlled to deliver the therapeutic dose over the prescribed duration. Start and stop times must be documented in the nursing or infusion record. | Most outpatient therapeutic infusions are delivered via peripheral IV access. The physical establishment of IV access is included in the primary code (96365) and is not separately reportable. Rate adjustments made during the infusion for clinical reasons (e.g., slowing infusion due to reaction) extend actual infusion time and may add additional 96366 units if total time crosses the 31-minute threshold into a new hourly increment. |
| Central Venous Access Infusion | When a patient has a tunneled central venous catheter (e.g., Port-a-Cath, Hickman), PICC line, or other central access device, the infusion is administered through this device. Central access is typically used in oncology patients, those receiving long-term immunosuppression, or patients with poor peripheral access. | The existence of central access does not change which CPT code is reported — 96366 applies regardless of venous access site. The central access device maintenance (e.g., flushing, dressing change) may be separately reportable with specific nursing HCPCS codes in certain settings but is not included in 96366. If a port is accessed and infusion is administered, document access and infusion separately in the nursing record. |
| Concurrent vs. Sequential Additional-Hour Infusions | When a second distinct drug is initiated as a concurrent infusion (running simultaneously through the same IV line or a Y-site) after the primary infusion is underway, it is reported with 96368 — not with 96366. If a second drug is started after the first drug infusion is complete (sequential), and it is a new therapeutic substance, it is reported with 96367 for the first hour of the new drug, and 96366 may then apply to its additional hours if that drug’s infusion also exceeds one hour. | This is one of the highest-frequency coding errors in infusion billing. The distinction between concurrent (96368), sequential additional substance (96367), and additional hours of the same drug (96366) determines the entire coding construct for a multi-drug infusion encounter. Always identify: (1) what drug was started first and for how long, (2) whether subsequent drugs ran simultaneously or after the prior drug was complete, and (3) the total infusion time for each drug separately. |
Clinical Pearl
The CPT infusion hierarchy requires that the primary code reflect the highest-level service performed in the encounter — chemotherapy > therapeutic > hydration. If both chemotherapy (96413) and a therapeutic drug (96365) are administered in the same encounter, the chemotherapy code anchors the claim as the primary, and the therapeutic drug is reported as a sequential (96367) or concurrent (96368) infusion — not as 96365. Therefore, 96366 (additional hour of therapeutic infusion) would only apply in an encounter where therapeutic infusion is the highest-level service, or where the therapeutic drug was the first drug started and runs beyond one hour. This hierarchy rule is one of the most audited aspects of infusion coding, particularly in oncology settings.2
✅ Procedure Includes
- Each full additional hour (minimum 31 minutes) of IV infusion of a single therapeutic, prophylactic, or diagnostic substance, after the first 60 minutes have been reported with the primary code; each qualifying 60-minute increment after the first hour is one unit of 96366.
- Monitoring of the infusion during the additional hour(s) — observation for infusion reactions, vital sign assessment, and clinical surveillance by nursing or supervising clinical staff are bundled into the 96366 time period and are not separately reportable.
- Infusion rate management — any pump reprogramming, rate adjustments, bag changes (same drug), or line flushing between bags of the same substance performed during the additional hour period is included.
- Documentation of the additional hour — the clinical staff notation of start and stop times, the drug name, concentration, and volume administered during the additional infusion period is the foundation for 96366 billing; the code inherently requires contemporaneous time documentation.
- Routine IV site assessment during the additional infusion period — observation of the IV access site for infiltration, phlebitis, or positional flow issues is bundled into the infusion monitoring service.
❌ Excludes / Do Not Report Together
| Code | Description | Relationship |
|---|---|---|
| 96365 | IV infusion, therapeutic/prophylactic/diagnostic; initial, up to 1 hour | 96365 is the required primary code that must appear on the claim before 96366 can be reported. You cannot report 96366 without 96365 (or another primary code) as the anchor. They are not mutually exclusive — they are required partners — but they cannot be billed in the same CPT slot; each is a separate line item. |
| 96367 | Additional sequential IV infusion, up to 1 hour, new substance | 96367 is used when a different therapeutic drug is started sequentially after the first drug’s infusion is complete. Do not use 96366 for additional infusion time when the second drug is a distinct substance from the first — 96367 is the correct code for the first hour of the new sequential drug, and 96366 then applies only to additional hours of that same second drug if it also runs beyond one hour. |
| 96368 | Concurrent infusion | 96368 is a flat per-encounter code (not per-hour) for a drug infused simultaneously with the primary infusion. Never use 96366 to report additional time for a concurrent infusion; 96368 is reported once regardless of how long the concurrent infusion runs. |
| 96415 | Chemotherapy infusion, each additional hour | 96415 is the chemotherapy equivalent of 96366. When the primary infusion is a chemotherapy agent (reported with 96413), additional hours of that same agent are reported with 96415 — not 96366. Using 96366 in place of 96415 for chemotherapy infusions is a significant coding error that misrepresents the nature of the service. |
| 96361 | Hydration infusion, each additional hour | 96361 is the hydration equivalent of 96366. Do not use 96366 for additional hours of IV hydration (saline, lactated Ringer’s, dextrose solutions). If hydration runs beyond one hour, 96361 applies — and hydration infusion is always the lowest-hierarchy service in a multi-drug encounter. |
Bundling Alert
96366 carries a ZZZ global period and 10 documented NCCI bundling edit pairs as of 2026.1 Payer claim scrubbers will automatically reject 96366 when submitted without a valid primary code (96365 or equivalent) on the same date of service — this is the most common denial for this code. Additionally, billing 96366 alongside any of the Category III codes listed in the NCCI edits (e.g., 0543T, 0544T, 0569T-0574T, 0580T-0581T) will trigger a bundling denial; modifier -59 or an X-modifier (XE, XS, XP, XU) may bypass an indicator-1 edit only when chart documentation supports a genuinely distinct service. CARC 97 (payment included in allowance for another service) is the most common CARC code associated with bundling denials on 96366.1
🌳 Code Tree — Medicine: Therapeutic, Prophylactic, and Diagnostic Injections and Infusions
CPT 96360-96379 Medicine: Hydration, Therapeutic, Prophylactic, Diagnostic Injections and Infusions
│
├── 96360-96361 Hydration Infusion
│ ├── 96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour (Global: XXX)
│ └── 96361 Intravenous infusion, hydration; each additional hour [Add-on] (Global: ZZZ)
│
├── 96365-96368 Therapeutic, Prophylactic, or Diagnostic IV Infusion (Non-Chemotherapy)
│ ├── 96365 IV infusion, therapeutic/prophylactic/diagnostic; initial, up to 1 hour (Global: XXX)
│ ├── ▶▶ 96366 ◀◀ IV infusion, therapeutic/prophylactic/diagnostic; each additional hour [Add-on] ← YOU ARE HERE (Global: ZZZ)
│ ├── 96367 Additional sequential IV infusion, new substance, up to 1 hour [Add-on] (Global: ZZZ)
│ └── 96368 Concurrent infusion [Add-on] (Global: ZZZ)
│
├── 96369-96371 Subcutaneous Infusion
│ ├── 96369 Subcutaneous infusion for therapy or prophylaxis; initial, up to 1 hour (Global: XXX)
│ ├── 96370 Subcutaneous infusion; each additional hour [Add-on] (Global: ZZZ)
│ └── 96371 Additional pump set-up with administration [Add-on] (Global: ZZZ)
│
└── 96372-96379 Injections
├── 96372 Therapeutic/prophylactic/diagnostic injection, IM or SC (Global: XXX)
├── 96374 Therapeutic IV push, single/initial substance (Global: XXX)
├── 96375 Each additional sequential IV push, new substance [Add-on] (Global: ZZZ)
└── 96376 Each additional sequential IV push, same substance [Add-on] (Global: ZZZ)
💰 RVU & Reimbursement Profile
| Component | Value |
|---|---|
| Work RVU | 0.18 |
| Global Period | ZZZ (add-on code; inherits global period of primary) |
| Bilateral Indicator | 3 (bilateral concept does not apply) |
| Assistant Surgeon | Not payable |
| Co‑Surgeon | Not payable |
| Team Surgery | Not payable |
| PC/TC Split | No (indicator 0 — no professional/technical split) |
| Modifier -51 Exempt | Yes (add-on code — not subject to multiple procedure reduction) |
| Anesthesia | Not applicable |
Bilateral Billing Rules
CPT 96366 is an IV infusion add-on code with a bilateral indicator of 3, meaning the bilateral surgery concept is entirely inapplicable. Modifiers -50, -RT, and -LT are never appropriate on this code. As a ZZZ add-on code, 96366 is also exempt from the multiple procedure reduction rule (modifier -51 does not apply). The low work RVU of 0.18 reflects that the value of this service resides primarily in the practice expense component (0.45) — the drug, nursing oversight, IV supplies, and infusion pump cost — rather than physician cognitive effort. The national average 2026 Medicare payment of approximately $21.38 applies equally to both facility and non-facility settings, which is unusual and reflects the predominantly supply/nursing-driven cost structure of this service.1
🏷️ Modifier Reference
| Modifier | Name | When to Apply |
|---|---|---|
| -59 | Distinct Procedural Service | Use when an NCCI edit pairs 96366 with another code and the services were genuinely distinct (separate substances, separate clinical encounters within the same day, or separate sessions). An indicator-1 edit pair can be bypassed with -59 when chart documentation supports a distinct service. The preferred approach per CMS is to use the more specific X-modifiers (XE, XS, XP, XU) instead of -59 when one of those more precisely describes the relationship. |
| -XE | Separate Encounter | Use when the additional-hour infusion was provided at a clinically distinct encounter that was separate in time from the primary service on the same calendar date — for example, when a patient returns for a second infusion session later the same day. Documentation must support two distinct encounters. |
| -XS | Separate Structure | Use when two services are rendered on two different body structures or anatomical sites — less commonly applicable to infusion coding but relevant when IV access sites are truly separate (e.g., two separate IV lines for two distinct drugs at distinct anatomical locations and payer requires distinction). |
| -XP | Separate Practitioner | Use when two services are rendered by separate practitioners, each billing independently — relevant in group practice or multi-provider infusion center settings where 96365 is billed by one provider and 96366 by another, though this is uncommon. |
| -XU | Unusual Non-Overlapping Service | Use when the service is not an overlap with a bundled code even though the edit typically fires — the most commonly used X-modifier for infusion NCCI edit bypasses when the clinical documentation supports a genuinely non-overlapping additional-hour service. |
| -GA | ABN on File | Append to 96366 when an Advance Beneficiary Notice has been obtained from a Medicare patient because the additional infusion hour may not meet Medicare medical necessity criteria (e.g., infusion duration extending beyond LCD-covered limits). Protects the provider’s ability to bill the patient if denied. |
| -GY | Statutory Exclusion | Use when 96366 is for a service statutorily excluded from Medicare coverage (e.g., certain experimental drugs or home infusion settings not covered under Part B). The provider may bill the patient directly. Do not use with -GA on the same line. |
| -GZ | No ABN on File, Denial Expected | Use when additional-hour infusion is expected to be denied and no ABN was obtained. The provider cannot bill the patient; this modifier signals to the payer that the provider acknowledges lack of ABN. |
| -KX | LCD Requirements Met | Append when billing 96366 for an infusion requiring attestation that LCD criteria have been met — commonly used for IVIG infusions billed under CMS LCD for Immune Globulins, confirming that all policy requirements (diagnosis, trial of alternatives, etc.) are satisfied.3 |
| -33 | Preventive Service | Applicable when the infusion is the delivery mechanism for a USPSTF A/B recommended preventive service (rare for therapeutic infusions; primarily relevant for certain vaccine or prophylactic drug administrations). Waives patient cost-sharing under the ACA. |
Note: Modifiers -RT, -LT, -50, -E1-E4, -25, -24, -52, -53, -58, -78, -79, -80, -81, -82, -62, -26, and -TC are not applicable to CPT 96366.
🩺 Common ICD‑10‑CM Pairings
Primary Diagnosis Group — Autoimmune / Inflammatory Conditions
| ICD‑10 | Description | HCC? | Notes |
|---|---|---|---|
| M05.79 | Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement | No | One of the most common diagnoses for biologic infusion (infliximab, abatacept, tocilizumab); code to the most specific site and RF status. RA is a top indication for prolonged therapeutic infusion encounters where 96366 is routinely generated. |
| M32.10 | Systemic lupus erythematosus, organ or system involvement unspecified | No | SLE managed with IV belimumab (Benlysta) requires 1-hour infusions; additional hours may be billed if the protocol is extended due to reactions or dose escalation. Always code the most specific SLE manifestation if organ involvement is documented. |
| K50.90 | Crohn’s disease of small intestine, unspecified, without complications | No | Infliximab and vedolizumab infusions for IBD commonly run 2-3 hours; 96366 ×1-2 is routinely appropriate. Code to the most specific Crohn’s subtype and complication status — avoid unspecified codes when documentation supports greater specificity. |
| G35 | Multiple sclerosis | No | Natalizumab (Tysabri) 60-minute infusion plus observation; some MS biologics have multi-hour infusion protocols. Rituximab use for MS may generate multiple 96366 units. This code is the most specific available for MS and is acceptable as a billable ICD-10-CM code. |
| G61.0 | Guillain-Barré syndrome | No | IVIG administration for GBS is a major indication for multi-hour infusion over several days; 96366 is expected and appropriate. Document total infusion time with start/stop times for each day of treatment. |
Secondary Group — Infectious Disease / Immunodeficiency
| ICD‑10 | Description | HCC? | Notes |
|---|---|---|---|
| B20 | Human immunodeficiency virus (HIV) disease | Yes (HCC) | IV antiretrovirals or prophylactic antivirals/antifungals in advanced HIV may require prolonged infusion times. B20 is an HCC-relevant code; accurate capture supports risk adjustment and must be documented by the treating provider with confirmation in the medical record. |
| D83.9 | Common variable immunodeficiency, unspecified | No | IVIG replacement therapy for CVID is one of the most common and clearly supported IVIG indications under CMS LCD. IVIG infusion typically runs 2-4 hours depending on dose and product; 96366 ×1-3 may be appropriate. |
Etiology / Complication
| ICD‑10 | Description | HCC? | Notes |
|---|---|---|---|
| D70.9 | Neutropenia, unspecified | No | G-CSF or other IV supportive agents in neutropenic patients may qualify; however, code to the specific underlying cause of neutropenia when documented (drug-induced, congenital, etc.) rather than defaulting to unspecified. |
| C80.1 | Malignant (primary) neoplasm, unspecified | Yes (HCC) | When the specific malignancy is not documented and the provider has not specified the primary site, C80.1 may be used — but this should be a last resort. When 96366 is used for a non-chemotherapy supportive infusion in a cancer patient (e.g., IV iron, bisphosphonate), the primary malignancy diagnosis supports medical necessity and must be captured. C80.1 is an HCC code with significant risk adjustment impact. |
Coding Specificity Reminder
CPT 96366 has extremely broad clinical applicability, but the ICD-10-CM diagnosis code is the primary driver of whether the claim will be paid — medical necessity is established by the diagnosis, not by the CPT code itself. For IVIG infusions specifically, CMS LCD for Immune Globulins (available via CMS MCD search) maintains a closed list of covered diagnoses with specific documentation requirements; only codes from that covered diagnosis list will support Medicare payment, and modifier -KX is required to attest that LCD criteria have been met.3 Always code the underlying condition to the highest specificity available — avoid unspecified codes such as D83.9 when more specific immunodeficiency documentation exists, and never use a symptom code as the primary diagnosis when the established underlying condition is documented and known.
🏥 MS‑DRG Considerations
CPT 96366 is a Medicine section add-on code and does not independently drive an MS-DRG assignment. When a patient is admitted inpatient and receives therapeutic IV infusions, the ICD-10-PCS procedure codes (e.g., 3E04305 — Introduction of Other Therapeutic Substance into Central Vein) capture the infusion for DRG purposes on the facility claim, while 96366 is reported only on the professional Part B claim by the billing provider. The underlying diagnoses — such as G35.A (multiple sclerosis), M05.79 (rheumatoid arthritis), or C80.1 (malignant neoplasm) — are the primary DRG drivers, mapping to MDC 01 (Nervous System), MDC 05 (Circulatory System), or MDC 17 (Hematologic/Immunologic), respectively. In outpatient hospital settings, 96366 falls under the OPPS and is subject to APC packaging rules — verify current APC assignment as infusion add-on codes may be conditionally packaged depending on the primary procedure and encounter context.
🔧 ICD‑10‑PCS Equivalents
| PCS Code | Full Description | Modality |
|---|---|---|
| 3E03305 | Introduction of Other Therapeutic Substance into Peripheral Vein, Percutaneous Approach | IV Therapeutic Infusion — Peripheral |
| 3E04305 | Introduction of Other Therapeutic Substance into Central Vein, Percutaneous Approach | IV Therapeutic Infusion — Central |
| 3E033VZ | Introduction of Hormone into Peripheral Vein, Percutaneous Approach | IV Hormonal Agent (e.g., corticosteroid infusion) |
| 3E0336Z | Introduction of Nutritional Substance into Peripheral Vein, Percutaneous Approach | IV Nutritional Substance |
PCS Character Analysis (Representative code: 3E03305 — Peripheral Vein, Other Therapeutic Substance)
| Position | Character | Value | Definition |
|---|---|---|---|
| 1 | Section | 3 | Administration — the section covering all procedures that introduce a substance into or onto the body, including infusions, injections, irrigations, and transfusions. |
| 2 | Body System | E | Physiological Systems and Anatomical Regions — the broad body system designation for administration procedures, covering all anatomical regions where substances may be introduced. |
| 3 | Root Operation | 0 | Introduction — defined as “putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.” This precisely maps to IV infusion of a therapeutic or prophylactic drug. |
| 4 | Body Part | 3 | Peripheral Vein — designates peripheral venous access (antecubital, forearm, hand, foot). Central vein (character 4 = 4) would apply when a PICC, port, or tunneled central catheter is used. |
| 5 | Approach | 3 | Percutaneous — IV catheter insertion through intact skin into the vessel is always percutaneous. Open or endoscopic approaches are not applicable to standard IV infusion. |
| 6 | Device | 0 | No Device — no device is left in the body at the conclusion of the procedure; the IV catheter is removed after infusion. |
| 7 | Qualifier | 5 | Other Therapeutic Substance — the broad qualifier for non-specific therapeutic drugs that do not have a dedicated qualifier value. More specific qualifiers exist for hormones, enzymes, nutritional substances, and blood products. |
Root Operation Comparison
- Introduction (0) vs. Irrigation (1): Introduction covers the administration of a distinct therapeutic or prophylactic substance — always the correct root for IV drug infusions. Irrigation (1) applies when a body cavity or space is washed/cleansed with a fluid, not when a drug is being administered for its systemic therapeutic effect.
- Peripheral Vein (3) vs. Central Vein (4): This distinction in body part character is clinically important in the inpatient PCS context and must reflect the actual access site documented in the nursing or procedure note. A PICC line, Hickman catheter, or implanted port codes to Central Vein (4), which may affect complication and comorbidity designation for DRG purposes in certain contexts.
- Other Therapeutic Substance (5) vs. Anti-Infective (1): When the drug infused is specifically an antibiotic, antiviral, or antifungal, qualifier 1 (Anti-Infective) is more precise than qualifier 5 (Other Therapeutic Substance). Accurate qualifier selection in PCS coding improves clinical documentation specificity and supports correct DRG assignment when IV anti-infectives are clinically significant.
📝 Coding Examples
Example 1
Clinical Scenario: A 52-year-old woman with Crohn’s disease of the large intestine with recurrent acute exacerbations presents to an outpatient infusion center for her scheduled infliximab (Remicade) infusion. The nursing record documents infusion started at 9:00 AM and completed at 11:45 AM — a total of 165 minutes (2 hours 45 minutes). The infliximab is the only drug administered. No E/M service is performed. The physician supervising the infusion center reviews the infusion record and co-signs the nursing documentation.
| Field | Code | Rationale |
|---|---|---|
| CPT 1 | 96365 | Primary code for the initial hour of therapeutic IV infusion; required anchor for 96366. Reports the first 60 minutes of infliximab infusion. |
| CPT 2 | 96366 ×2 | 165 total minutes − 60 minutes (first hour) = 105 additional minutes. 61-120 minutes = 1 unit of 96366; 121-165 minutes = 2nd unit of 96366 (45 minutes remaining > 30-minute minimum). Two units of 96366 are supported by the documented infusion time. |
| PDx | K51.90 | Ulcerative colitis, unspecified, without complications — code to the most specific IBD subtype documented; if large intestine Crohn’s is confirmed, K50.10 would be more accurate. |
Note
The 31-minute rule for the last additional hour is critical here: 165 minutes yields exactly 45 additional minutes beyond the 2nd completed hour, which exceeds the 30-minute floor, so the 2nd unit of 96366 is billable. If the infusion had ended at 2 hours and 25 minutes (145 total), only one unit of 96366 would be supported. Start and stop times must be documented by nursing contemporaneously — reconstructed times are a significant compliance risk.
Example 2
Clinical Scenario: A 35-year-old male with common variable immunodeficiency (CVID) receives IVIG infusion at his rheumatologist’s outpatient office. IVIG infusion begins at 8:30 AM and ends at 1:00 PM — 4.5 hours (270 minutes). The physician documents that all CMS LCD criteria for IVIG have been met per the Immune Globulins LCD. A separate, identifiable E/M visit is performed and documented prior to the infusion to address a new symptom of sinusitis.
| Field | Code | Rationale |
|---|---|---|
| CPT 1 | 99213-25 | Separately identifiable E/M for new symptom of sinusitis; modifier -25 applied to the E/M (not to the infusion code). The E/M must be documented as distinct from the routine infusion oversight. |
| CPT 2 | 96365-KX | Initial hour of IVIG therapeutic infusion; modifier -KX appended to attest that CMS LCD Immune Globulins criteria are satisfied. |
| CPT 3 | 96366-KX ×3 | 270 total minutes − 60 minutes = 210 additional minutes; 210 ÷ 60 = 3.5, but only 3 full additional-hour increments of ≥31 minutes each are reportable. 61-120 min = unit 1; 121-180 min = unit 2; 181-240 min = unit 3; the remaining 30 minutes (241-270) does NOT meet the 31-minute minimum, so a 4th unit is not billable. KX appended to each 96366 unit. |
| PDx | D83.9 | Common variable immunodeficiency — primary diagnosis supporting IVIG medical necessity. |
Warning
Do NOT report 4 units of 96366 in this scenario — the final 30 minutes falls exactly at the floor and does not cross the 31-minute threshold. This is one of the most common overcoding patterns on IVIG infusion claims and a frequent target of post-payment audits. Every unit of 96366 beyond the first must independently clear the 31-minute threshold.
Example 3
Clinical Scenario: A hospital outpatient infusion center administers IV methylprednisolone (a therapeutic non-chemotherapy corticosteroid) to a 44-year-old woman with a relapsing-remitting MS exacerbation. The infusion runs 90 minutes. Following completion of the methylprednisolone, the nurse hangs a bag of normal saline for IV hydration which runs an additional 45 minutes. The facility billing team is completing the claim.
| Field | Code | Rationale |
|---|---|---|
| CPT 1 | 96365 | Initial hour of therapeutic IV infusion (methylprednisolone); highest-hierarchy service in the encounter — therapeutic infusion outranks hydration in the CPT hierarchy. |
| CPT 2 | 96366 ×1 | 90 minutes of methylprednisolone infusion; 30 additional minutes beyond the first hour — this is exactly 30 minutes, which does NOT meet the 31-minute minimum. Therefore, 96366 is NOT billable for the methylprednisolone. |
| CPT 3 | 96361 | Hydration infusion, each additional hour — the 45-minute saline infusion qualifies (>30 minutes), but only if hydration was sequential after the therapeutic infusion ended AND hydration was medically necessary. Under CPT hierarchy, hydration is always secondary to therapeutic infusion; 96360 cannot be reported as primary when a therapeutic infusion was given the same day. 96361 is the correct add-on hydration code in this context. |
| PDx | G35 | Multiple sclerosis — primary diagnosis driving the therapeutic infusion and the clinical encounter. |
Global period reminder
CPT 96366 has a ZZZ global period and no independent pre/post-operative period of its own — it can be billed every time a qualifying additional infusion hour is documented on any date of service. There is no frequency restriction based on global period for repeat infusion encounters (e.g., weekly IVIG cycles or monthly biologic infusions). Frequency limitations are imposed by payer LCD/NCD policy and medical necessity criteria for the specific drug — not by the CPT global period designation.
⚠️ Common Coding Pitfalls
-
Pitfall 1: Billing 96366 without a valid primary code on the same claim. 96366 is an add-on code and will be automatically rejected by claim scrubbers if submitted without 96365 (or another qualifying primary infusion code) on the same date of service. This includes situations where 96365 was billed on a prior date or a separate claim — the primary and add-on must appear together on the same claim submission. Verify that your practice management system links add-on codes to their primary codes before submission.
-
Pitfall 2: Failing to apply the 31-minute rule correctly, leading to over- or under-coding. Each additional unit of 96366 requires a minimum of 31 minutes of infusion time beyond the last completed 60-minute increment. A total infusion of 90 minutes generates zero units of 96366 (only 30 additional minutes beyond hour 1); 91 minutes generates one unit. Staff who round up infusion times or fail to document stop times precisely create billing inaccuracies in both directions that are audit targets.
-
Pitfall 3: Using 96366 instead of 96415 for chemotherapy infusions. When the primary service is a chemotherapy drug (reported with 96413), additional hours of that chemotherapy are reported with 96415 — not 96366. This is a frequent cross-coding error in multi-drug oncology infusion encounters, particularly when practices use generic “additional hour” templates. The drug’s classification (chemotherapy vs. therapeutic) determines which add-on code applies.
-
Pitfall 4: Using 96366 instead of 96367 or 96368 when a second drug is involved. 96366 reports additional hours of the same drug from the primary infusion. When a new, different drug is added sequentially, 96367 is required for its first hour; only if that second drug also runs beyond one hour does 96366 apply to its additional hours. When a second drug runs concurrently (simultaneously), 96368 is used — a single flat code regardless of duration. Confusing these three codes is the single most common infusion coding error pattern and a high-priority NCCI edit area.
-
Pitfall 5: Omitting modifier -KX on IVIG claims. For Medicare patients receiving IVIG, CMS LCD for Immune Globulins requires modifier -KX on both 96365 and every unit of 96366 to attest that all LCD criteria are met. Missing -KX on any infusion code line results in medical necessity denial. Documentation in the medical record must support the KX attestation — including the specific diagnosis, failure of alternative therapies, and prescribing physician’s clinical rationale.
-
Pitfall 6: Billing 96366 for observation time rather than active infusion time. Some infusion protocols (e.g., natalizumab, ocrelizumab) require a mandatory post-infusion observation period for monitoring adverse reactions — typically 30-60 minutes after infusion completion. This observation time is NOT infusion time and does not count toward the 96366 time calculation. Only the period during which the drug solution is actively flowing through the IV line should be counted. Conflating observation time with infusion time leads to overcoding and is a recurrent audit finding in neurology and MS infusion centers.